Available models for in vitro proof-of-concept studies of RNA therapeutics for GNAO1 encephalopathy are patient-specific neurons and organoids derived from induced pluripotent stem cells (Akamine et al., 2020). The gene discussed is GNAO1; the disease is Encephalopathy.